neurocare group AG Announces Publication Confirming the Importance of Sleep for Effectiveness of Combined rTMS and CBT for OCD
November 21, 2022 10:00 ET
|
neurocare group AG
MUNICH, Nov. 21, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG expands international footprint with cooperation in the Middle East, the Republic of Ireland and Northern Ireland
September 05, 2022 03:00 ET
|
neurocare group AG
MUNICH, Sept. 05, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG and STIMIT AG announce strategic cooperation
August 23, 2022 16:00 ET
|
neurocare group AG
MUNICH, Aug. 23, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG obtains patent grant on treatment method for neuromodulation in Japan
June 23, 2022 11:00 ET
|
neurocare group AG
MUNICH, June 23, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG continues expansion with opening of first UK clinic in London
June 14, 2022 10:00 ET
|
neurocare group AG
MUNICH, June 14, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG Announces Recent Start of a Phase III Trial Examining the Cost-Effectiveness of TMS for Patients With Exposure Therapy-Resistant OCD
June 08, 2022 11:00 ET
|
neurocare group AG
MUNICH, June 08, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG announces TGA approval of Apollo TMS System with product launch at RANZCP Congress in Sydney
May 13, 2022 11:00 ET
|
neurocare group AG
MUNICH, May 13, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare Announces Entry Into Ketamine-Assisted Therapy Market Through Cooperation With Privatpraxis Dr. Scheib in Berlin
May 11, 2022 03:00 ET
|
neurocare group AG
MUNICH, May 11, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG announces participation at Clinical TMS Society 2022 Annual Meeting
May 10, 2022 08:00 ET
|
neurocare group AG
MUNICH, May 10, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
neurocare group AG announces Publication in Biological Psychiatry CNNI Revealing the First Clinically Actionable EEG Biomarker in ADHD
May 06, 2022 07:31 ET
|
neurocare group AG
MUNICH, May 06, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...